Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Hematologic Neoplasms 2Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic-Myeloproliferative Diseases 1Mycoses 1Mucormycosis 1Genetic Predisposition to Disease 1Candidiasis 1Breast Neoplasms 1Aspergillosis 1

Interventions

Specimen Handling 3Azacitidine 3ruxolitinib 2Melphalan 2Cyclophosphamide 2Busulfan 2Biopsy 2venetoclax 1posaconazole 1onvansertib 1merphos 1gilteritinib 1fludarabine phosphate 1fludarabine 1fedratinib 1axatilimab 1Whole-Body Irradiation 1Watchful Waiting 1Tranexamic Acid 1Tacrolimus 1Succimer 1Stem Cell Transplantation 1Rituximab 1Positron-Emission Tomography 1Pentetic Acid 1Methotrexate 1Janus Kinase Inhibitors 1Injections 1Hyperbaric Oxygenation 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Myelodysplastic-Myeloproliferative Diseases × posaconazole × Clear all
NCT04771130 2026-04-23

A Study of BGB-11417 in Participants With Myeloid Malignancies

BeOne Medicines

Phase 1/2 Recruiting
260 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡